Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Regulus Therapeutics (NASDAQ:RGLS) but lowers the price target from $12 to $11.

March 19, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Regulus Therapeutics but lowers the price target from $12 to $11.
While the reduction in price target could suggest a slightly less optimistic outlook on the stock's value, the maintenance of a Buy rating indicates continued confidence in the company's potential. This mixed signal could lead to a neutral short-term impact on the stock price, as investors weigh the lowered price target against the sustained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100